Procter & Gamble is a global consumer-staples leader selling daily-use products across beauty, grooming, health care, fabric and home care, and baby, feminine and family care in about 180 countries.
PG
· Consumer Defensive · Household & Personal Products
· Market cap $349.54B
QuantHub Original Research · Updated 2026-09-17
·
High QualityHigh-tier business, attractive-tier valuation, with 14.4% upside to $168.19 fair value but modest organic-growth guidance and no greater-than-30% upside.Fair Value
PG is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Maturing Phase
Procter & Gamble is a global consumer-staples leader selling daily-use products across beauty, grooming, health care, fabric and home care, and baby, feminine and family care in about 180 countries. Business quality is high because its brands, consumer insight, R&D, marketing scale and global distribution underpin leading category positions, including over 60% in blades and razors and over 35% in fabric care, while TTM gross, operating and net margins are 50.2%, 22.7% and 18.4%, respectively, and ROE is 29.8%. The investment debate is whether these strengths can overcome a maturing growth profile: revenue grew 1.5% year over year and earnings declined 17.1% year over year in the most recent quarter, while FY2027 organic-sales guidance is only 1%-3% amid roughly $1.0 billion after-tax input-cost headwinds. At $147.04, PG trades at 22.2x trailing earnings, 22.38x free cash flow and 17.63x EV/EBITDA, a cheap valuation regime versus its five-year history; the $168.19 fair-value estimate implies 14.4% upside, although the $149 average analyst target implies only 1.3% upside and reflects caution around near-term earnings and growth.
PG is classified as cheap relative to its five-year valuation history, but the market is assigning a restrained multiple because underlying growth is subdued and margins face material cost pressure. The shares trade at 22.2x trailing P/E, 22.38x P/FCF, 4.02x sales and 17.63x EV/EBITDA despite high margins and a 29.8% ROE. The $168.19 fair-value estimate supports 14.4% upside from $147.04, whereas the $149 average analyst target supports only 1.3% upside, illustrating a sentiment gap between a normalized valuation framework and near-term sell-side caution. Recent actions were mixed: Bernstein maintained Hold with a $149 target, Evercore ISI maintained Hold with a $161 target, Barclays maintained Hold with a $152 target, and Jefferies maintained Buy while reducing its target to $177. Investors are pricing FY2027 guidance of just 1%-3% organic growth, pressure from approximately $1.0 billion after-tax raw-material, energy and transportation costs, and execution uncertainty around restructuring and Thorne integration.
12–18 Month Outlook
By roughly March 2028, the central question will be whether P&G has converted its FY2027 restructuring, innovation and marketing investment into sustained volume and share recovery rather than merely protecting earnings through pricing. The base case is a still-maturing company with low-single-digit organic growth consistent with FY2027 guidance of 1%-3%, supported by strong cash generation and shareholder returns but constrained by an approximately $1.0 billion after-tax input-cost headwind. Upside would require Beauty momentum and Health Care share gains to broaden, with stabilization in Grooming and Baby, Feminine and Family Care after their FY2026 share losses. Downside would emerge if flat volumes, private-label trade-down and cost inflation persist, leaving the 22.7% operating margin under further pressure and limiting the path toward the $168.19 fair value.
Bull vs Bear
Bull Case
P&G's brand and distribution moat remains substantial, with reported worldwide category positions of over 60% in blades and razors, over 35% in fabric care, over 30% in home care and baby care, and nearly 30% in oral care and feminine care.
The company generates strong profitability and cash conversion, with TTM gross margin of 50.2%, TTM operating margin of 22.7%, TTM net margin of 18.4%, ROE of 29.8%, FY2026 operating cash flow of $19.6 billion and free cash flow per share of $6.57.
The stock is in a cheap regime relative to its five-year history, and the $168.19 fair-value estimate implies 14.4% upside from the current $147.04 share price.
Health Care gained 0.4 points of global segment share in FY2026, Beauty delivered 5% organic sales growth in FY2026, and the Thorne acquisition could extend P&G into premium vitamins, supplements, prevention and personalized wellness.
Management expects approximately $10 billion of FY2027 dividends and $5 billion of buybacks, providing a meaningful shareholder-return base while the company pursues productivity improvements.
Bear Case
Growth remains muted: FY2026 organic sales grew only 1%, fiscal Q4 organic sales were flat, and management guides to only 1%-3% organic growth in FY2027.
Earnings and margins face substantial pressure from approximately $1.0 billion after-tax of expected FY2027 raw-material, energy and transportation headwinds, alongside $150 million of interest expense headwinds, $150 million of lower non-operating income and $50 million of foreign-exchange pressure.
Competitive and private-label pressure is visible in FY2026 global segment-share declines of 0.3 points in Beauty, 0.4 points in Grooming and 0.2 points in Baby, Feminine and Family Care, while companywide volume was flat.
Operating margin declined 160 basis points to 22.7% in FY2026, demonstrating that investment, cost inflation and restructuring can outweigh modest reported sales growth.
P&G must complete up to 7,000 non-manufacturing overhead reductions by June 30, 2027 while integrating the proposed $3.8 billion Thorne acquisition, increasing operational, cultural, regulatory and financial execution risk.
Leadership & Competitive Position
Shailesh G. Jejurikar
Tenure0.7 yrs
Insider ownership0.225%
Beats guidance75% of qtrs
Capital allocationGood
Shailesh G. Jejurikar became Chairman, President and CEO on January 1, 2026 after joining P&G in 1989. He previously led Enterprise Markets and held leadership responsibilities across supply chain, IT, sales and global business services. Jon Moeller remains Executive Chairman, supporting continuity, but Jejurikar's CEO track record is still early. Capital allocation combines roughly $10 billion of planned FY2027 dividends and $5 billion of buybacks with 4.5%-5.5% of sales directed to capital expenditure and the proposed $3.8 billion Thorne acquisition.
Competitive Moat
narrowing
intangible assetsbrand
P&G reports worldwide positions of over 60% in blades and razors, over 35% in fabric care, over 30% in home care and baby care, nearly 30% in oral care and feminine care, and about 20% in retail hair care. In FY2026, global segment share declined 0.3 points in Beauty, 0.4 points in Grooming and 0.2 points in Baby, Feminine and Family Care; Fabric and Home Care was flat, while Health Care gained 0.4 points.
Disruption: Medium because private-label and branded competitors are constraining pricing power, as reflected in share losses across several major segments, though P&G's category positions and brand investment remain meaningful defenses.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
22.2x
23.89x
23.96x
21.72x
26.33x
P/S
4.02x
4.57x
4.41x
4.08x
4.64x
P/FCF
22.38x
23.24x
26.04x
22.32x
27.84x
P/S 4.02x vs 5yr range 4.08-4.64x (P25=4.08x, median=4.41x, P75=4.57x)
Price Outlook (5-Year)
Bear
$135
-1.6%/yr
Base
$168
2.8%/yr
fair value
Bull
$202
6.7%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Evidence of progress against management's 1%-3% organic-sales growth outlook and $6.89-$7.11 core-EPS range could demonstrate that innovation, pricing and productivity are offsetting cost headwinds.
high
2026-H2
Thorne acquisition closing
The proposed $3.8 billion acquisition of premium wellness and supplement company Thorne remains subject to regulatory approval and customary closing conditions and is expected later in calendar 2026.
medium
2027-06-30
Restructuring program completion
P&G's program targeting up to 7,000 non-manufacturing overhead reductions is scheduled to run through fiscal-year end June 30, 2027 and could improve the cost structure after planned two-year pretax restructuring costs of $1.5 billion-$2.0 billion.
medium
2027-H1
Volume and share stabilization
Improving volume and reversal of FY2026 share losses in Beauty, Grooming and Baby, Feminine and Family Care would support a more constructive growth and valuation narrative.
high
Risks
Input costs and trade disruption
high
FY2027 guidance includes approximately $1.0 billion after-tax of raw-material, energy and transportation headwinds. IEEPA tariff exposure has eased after the U.S. Supreme Court invalidated those tariffs on February 20, 2026, but commodity, freight, energy and trade-disruption exposure remains material.
Modest organic growth
high
FY2026 organic sales rose only 1%, fiscal Q4 organic sales were flat, and FY2027 guidance calls for 1%-3% organic growth, leaving limited room for volume, pricing or execution misses.
Pricing, volume and private-label pressure
medium
FY2026 companywide volume was flat, and global segment share fell 0.3 points in Beauty, 0.4 points in Grooming and 0.2 points in Baby, Feminine and Family Care as consumers can trade down or select branded alternatives.
Restructuring and acquisition execution
medium
P&G is implementing up to 7,000 non-manufacturing overhead reductions through June 30, 2027 while pursuing the proposed $3.8 billion Thorne acquisition. The combination creates operational, cultural, regulatory and integration risk.
Capital allocation and impairment exposure
low
Planned FY2027 dividends and buybacks total about $15 billion before the Thorne cash acquisition, which could reduce flexibility if earnings weaken. The Gillette indefinite-lived brand had a $12.8 billion carrying value at June 30, 2026 and remains exposed to impairment risk if demand, pricing or macro conditions deteriorate.
Regulatory, product safety and cyber exposure
medium
P&G faces ongoing product-safety, legal, regulatory, cybersecurity, supply-chain, foreign-exchange and interest-rate risks across a global consumer-products organization operating in about 180 countries and territories.
Growth Engines
Beauty category innovationmature
Beauty is a global recurring-use category within P&G's broad consumer-products footprint. The segment delivered 5% organic growth in FY2026, but P&G does not disclose a numerical companywide TAM.
Health Care expansionscaling
Health Care operates in global daily-use consumer health categories and gained 0.4 points of share in FY2026. The proposed Thorne acquisition would expand the addressable opportunity into vitamins, minerals, supplements, prevention and personalized wellness.
Productivity and restructuring savingsscaling
The opportunity is internal margin expansion rather than a separate external TAM. P&G is targeting up to 7,000 non-manufacturing overhead reductions by fiscal 2027 end.
Emerging market household penetrationmature
P&G operates in about 65 countries, sells in about 180 countries and says it serves about 5 billion people annually, leaving a broad global consumer base across recurring household and personal-care categories.
P&G reported FY2026 results and maintained FY2027 outlook
FY2026 net sales increased 3% and organic sales increased 1%, while fiscal Q4 organic sales were flat and Q4 core EPS declined 3% to $1.43. Management guided FY2027 organic sales growth of 1%-3% and core EPS of $6.89-$7.11.
2026-08-04
P&G announced proposed $3.8 billion Thorne acquisition
The transaction would broaden P&G's Health Care presence into premium wellness and supplements, but remains subject to regulatory approval and customary conditions.
2026-08-28
P&G filed its 2026 proxy statement
The filing reported that directors and executive officers as a group beneficially owned 0.225% of common stock as of June 30, 2026, indicating modest rather than controlling insider alignment.
2026-02-20
U.S. Supreme Court invalidated IEEPA tariffs
P&G's FY2026 annual report stated that the company had paid about $200 million of affected tariffs and recognized recovery of half during fiscal Q4, easing one component of tariff exposure while leaving broader input-cost pressure intact.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is PG undervalued?
PG is currently fairly valued at $146.22 vs. our fair value estimate of $168.19 (+15% upside).
What is PG's fair value?
QuantHub Research estimates PG's fair value at $168.19 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for PG?
Input costs and trade disruption: FY2027 guidance includes approximately $1.0 billion after-tax of raw-material, energy and transportation headwinds. IEEPA tariff exposure has eased after the U.S. Supreme Court invalidated those tariffs on February 20, 2026, but commodity, freight, energy and trade-disruption exposure remains material. Modest organic growth: FY2026 organic sales rose only 1%, fiscal Q4 organic sales were flat, and FY2027 guidance calls for 1%-3% organic growth, leaving limited room for volume, pricing or execution misses. Pricing, volume and private-label pressure: FY2026 companywide volume was flat, and global segment share fell 0.3 points in Beauty, 0.4 points in Grooming and 0.2 points in Baby, Feminine and Family Care as consumers can trade down or select branded alternatives.
What is the bull case for PG?
P&G's brand and distribution moat remains substantial, with reported worldwide category positions of over 60% in blades and razors, over 35% in fabric care, over 30% in home care and baby care, and nearly 30% in oral care and feminine care. The company generates strong profitability and cash conversion, with TTM gross margin of 50.2%, TTM operating margin of 22.7%, TTM net margin of 18.4%, ROE of 29.8%, FY2026 operating cash flow of $19.6 billion and free cash flow per share of $6.57. The stock
How confident is QuantHub in PG?
QuantHub has moderate conviction in PG. Research last updated 2026-09-17.